Skip to main content

Advertisement

SpringerLink
Log in

Merkel Cell Carcinoma: Is there a Role for 2-Deoxy-2-[F-18]fluoro-d-glucose-Positron Emission Tomography/Computed Tomography?

  • Brief Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Purpose

2-Deoxy-2-[F-18]fluoro-d-glucose (FDG)–positron emission tomography (PET)/computed tomography (CT) is becoming widely available as a powerful imaging modality, combining the ability to detect active metabolic processes and their morphologic features in a single study. The role of FDG-PET/CT is proven in lymphoma, melanoma, colorectal carcinoma, and other cancers. However, there are rare malignancies such as Merkel cell carcinoma that can potentially be evaluated with PET/CT. We were therefore prompted to review our experience with FDG-PET/CT in the management of patients with Merkel cell carcinoma.

Procedures

This is a retrospective case series of six patients with Merkel cell carcinoma, 58–81 years old (average 69 ± 8.3), who had whole-body PET/CT at our institution from January 1st, 2003 to August 31st, 2005. Two patients were women and four were men. Reinterpretation of the imaging studies for accuracy and data analysis from medical records were performed.

Results

Twelve examinations were acquired for the six patients (one patient had six PET/CT, one patient had two PET/CT, and four patients had one PET/CT). The injected FDG doses ranged 381.1–669.7 MBq (average 573.5 ± 70.3). Four patients had the PET/CT as part of initial staging, and two patients had the exam for restaging (after surgery and XRT). A total of six Merkel lesions (pancreas, adrenal, lip, submandibular lymph nodes, cervical lymph nodes, and parapharyngeal soft tissue) were identified in three patients and confirmed on histopathological examination. The FDG uptake in these areas was intense, with maximum standardized uptake value (SUVmax) values of 5–14 (average 10.4 ± 3.8). In one patient, the PET/CT scan identified abnormal focal distal sigmoid uptake that was biopsied and diagnosed as adenocarcinoma. Two patients had negative scans and had no clinical evidence of disease on follow-up office visits (up to one year after PET/CT).

Conclusions

This case series suggests that FDG-PET/CT may have a promising role in the management of patients with Merkel cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Nghiem P, McKee PH, Haynes HA (2001) Merkel cell (cutaneous neuroendocrine) carcinoma. In: Sober AJ, Haluska FG (eds) Skin cancer. Hamilton, Ontario: BC Decker Inc., pp 127–141

    Google Scholar 

  2. Toker C (1972, January) Trabecular carcinoma of the skin. Arch Dermatol 105(1):107–110, January

    Article  PubMed  CAS  Google Scholar 

  3. Sidhu GS, Chandra P, Cassai ND (2005, May–August) Merkel cells, normal and neoplastic: an update. Ultrastruct Pathol 29(3–4):287–294

    Article  PubMed  Google Scholar 

  4. Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG (2005, April 1) Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 23(10):2300–2309

    Article  PubMed  Google Scholar 

  5. Gambhir SS (2002, September) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2(9):683–693

    Article  PubMed  CAS  Google Scholar 

  6. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL (1999, November) Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 213(2):521–525

    PubMed  CAS  Google Scholar 

  7. Wasserberg N, Schachter J, Fenig E, Feinmesser M, Gutman H (2000, February) Applicability of the sentinel node technique to Merkel cell carcinoma. Dermatol Surg 26(2):138–141

    Article  PubMed  CAS  Google Scholar 

  8. Durani BK, Klein A, Henze M, Haberkorn U, Hartschuh W (2003, June) Somatostatin analogue scintigraphy in Merkel cell tumours. Br J Dermatol 148(6):1135–1140

    Article  PubMed  CAS  Google Scholar 

  9. Castagnoli A, Biti G, De Cristofaro MT, et al. (1992) Merkel cell carcinoma and iodine-131 metaiodobenzylguanidine scan. Eur J Nucl Med 19(10):913–916

    Article  PubMed  CAS  Google Scholar 

  10. Watanabe N, Shimizu M, Kageyama M, Kitagawa K, Hayasaka S, Seto H (1998, August) 123I-MIBG SPECT of Merkel cell carcinoma. Br J Radiol 71(848):886–887

    PubMed  CAS  Google Scholar 

  11. Von Moll L, McEwan AJ, Shapiro B, et al. (1987, June) Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. J Nucl Med 28(6):979–988

    PubMed  Google Scholar 

  12. Lampreave JL, Benard F, Alavi A, Jimenez-Hoyuela J, Fraker D (1998, December) PET evaluation of therapeutic limb perfusion in Merkel's cell carcinoma. J Nucl Med 39(12):2087–2090

    PubMed  CAS  Google Scholar 

  13. Wong CO, Pham AN, Dworkin HJ (2000, March) F-18 FDG Accumulation in an Octreotide negative Merkel cell tumor. Clin Positron Imaging 3(2):71–73

    Article  PubMed  Google Scholar 

  14. Nguyen BD (2002, December) Positron emission tomographic imaging of Merkel cell carcinoma. Clin Nucl Med 27(12):922–923

    Article  PubMed  Google Scholar 

  15. Lin O, Thomas A, Singh A, Greenspan B (2004, November) Complementary role of positron emission tomography in Merkel cell carcinoma. South Med J 97(11):1110–1112

    Article  PubMed  Google Scholar 

  16. Yao M, Smith RB, Hoffman HT, Funk GF, Graham MM, Buatti JM (2005, April) Merkel cell carcinoma: two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance. Am J Clin Oncol 28(2):205–210

    Article  PubMed  Google Scholar 

  17. Scanga DR, Martin WH, Delbeke D (2004, February) Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med 29(2):86–90

    Article  PubMed  Google Scholar 

  18. Talbot JN, Kerrou K, Missoum F, et al. (2005, August 5) 6-[F-18]Fluoro-L: -DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]Fluoro-d: -glucose positron emission tomography or pentetreotide-(111In) SPECT Data. Mol Imaging Biol 1–5

Download references

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, Department of Radiology, Stanford University Medical Center, 300 Pasteur Drive, H-0101, Stanford, CA, 94305, USA

    A. Iagaru, A. Quon & I. R. McDougall

  2. Division of Nuclear Medicine, Departments of Radiology and Bioengineering, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, James H. Clark Center, 318 Campus Drive, 150 East Wing, 1st Floor, Stanford, CA, 94305-5427, USA

    S. S. Gambhir

Authors
  1. A. Iagaru
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Quon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. R. McDougall
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. S. Gambhir
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. S. Gambhir.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iagaru, A., Quon, A., McDougall, I.R. et al. Merkel Cell Carcinoma: Is there a Role for 2-Deoxy-2-[F-18]fluoro-d-glucose-Positron Emission Tomography/Computed Tomography?. Mol Imaging Biol 8, 212–217 (2006). https://doi.org/10.1007/s11307-006-0047-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-006-0047-2

Key words

Search

Navigation